超声乳化联合或不联合CyPass微型支架植入术后5年角膜内皮细胞丢失与形态学变化
本研究为COMPASS随机临床试验的3年安全性扩展分析,评估开角型青光眼合并白内障患者行超声乳化联合CyPass微型支架植入(n=282)或单纯超声乳化(n=67)后角膜内皮细胞变化。结果显示微型支架组第60个月内皮细胞密度平均变化为-20.4%,对照组为-10.1%,两组细胞形态学变化无统计学显著差异。结论认为单纯超声乳化后内皮细胞丢失为急性且3个月后稳定,而联合微型支架植入后内皮细胞丢失持续至少5年。
要点
- 微型支架组第60个月内皮细胞密度平均变化-20.4%,对照组-10.1%。
- 两组细胞形态学变化无统计学显著差异。
- 9例不良事件可能与内皮细胞丢失相关,其中3眼短暂局灶性角膜水肿、4眼需修剪支架。
核心结论
- 开角型青光眼患者单纯超声乳化后内皮细胞丢失为急性且3个月后稳定,联合微型支架植入后内皮细胞丢失持续至少5年。
- 与内皮细胞丢失相关的临床发现不常见(植入眼的3.3%),提示内皮细胞丢失通常为亚临床现象。
研究设计与样本
- COMPASS随机临床试验的3年安全性扩展,为多中心研究的事后分析。
- 纳入行微型支架植入联合超声乳化者282眼,单纯超声乳化者67眼。
- 采用角膜内皮显微镜评估内皮细胞丢失,包括内皮细胞密度、变异系数和六角形细胞百分比相对于基线的变化。
主要发现
- 术前内皮细胞密度微型支架组为2432.6 cells/mm2(95%CI 2382.8-2482.4),对照组为2434.5 cells/mm2(95%CI 2356.5-2512.4)。
- 第48个月和第60个月内皮细胞丢失微型支架组大于对照组。
- 第60个月内皮细胞密度平均变化百分比微型支架组为-20.4%(95%CI -23.5%至-17.5%),对照组为-10.1%(95%CI -13.9%至-6.3%)。
- 两组细胞形态学相对于基线的变化无统计学显著差异。
- 9例不良事件可能与内皮细胞丢失相关,包括3眼短暂局灶性角膜水肿和4眼因支架突出需修剪。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize long-term changes in corneal endothelial cells after phacoemulsification with or without supraciliary Micro-Stent (Alcon) implantation in eyes with open-angle glaucoma (OAG) and visually significant cataract. DESIGN: Three-year safety extension of a 2-year randomized clinical trial. METHODS: Patients from the multicenter Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery (COMPASS) trial who underwent Micro-Stent implantation plus phacoemulsification (n = 282) or phacoemulsification alone (n = 67) were analyzed post hoc. Specular microscopy was used to assess endothelial cell loss (ECL), including changes from baseline in endothelial cell density (ECD), coefficient of variation, and percentage of hexagonal cells. RESULTS: Preoperative ECDs in the microstent group (2,432.6 cells/mm2 [95% confidence interval [CI], 2,382.8-2,482.4 cells/mm2]) were similar to those in the control group (2,434.5 cells/mm2 [95% CI, 2,356.5-2,512.4 cells/mm2]) groups. ECL at months 48 and 60 was greater in the Micro-Stent group than in the control group. At month 60, the mean percent of changes in ECD was -20.4% (95% CI, -23.5% to -17.5%) in the Micro-Stent group and -10.1% (95% CI, -13.9% to -6.3%) in the control group. No statistically significant between-group changes from baseline in cellular morphology were observed. Nine adverse events were possibly related to ECL, including 3 eyes with transient focal corneal edema and 4 eyes that required Micro-Stent trimming due to protrusion. CONCLUSIONS: In eyes with OAG, ECL after phacoemulsification is acute and stabilizes after 3 months, whereas ECL after phacoemulsification plus Micro-Stent implantation proceeds for at least 5 years. Clinical findings associated with ECL in these eyes were uncommon (3.3% of implanted eyes), suggesting that ECL is generally a subclinical phenomenon.
引用
- Lass JH, Benetz BA, He J, et al. Corneal Endothelial Cell Loss and Morphometric Changes 5 Years after Phacoemulsification with or without CyPass Micro-Stent. Am J Ophthalmol. 2019. PMID: 31377278. doi:10.1016/j.ajo.2019.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。